BBLG — Bone Biologics Income Statement
0.000.00%
Last trade - 00:00- $2.36m
- -$0.96m
Annual income statement for Bone Biologics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | C2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 0 | 0 | 0 | 0 | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 0.825 | 1.1 | 3.67 | 9.84 | 4.22 |
| Operating Profit | -0.825 | -1.1 | -3.67 | -9.84 | -4.22 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.82 | -1.61 | -1.48 | -8.95 | -4.11 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.82 | -1.61 | -1.48 | -8.95 | -4.11 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.82 | -1.61 | -1.48 | -8.95 | -4.11 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.82 | -1.61 | -1.48 | -8.95 | -7.32 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -150 | -85.1 | -31.2 | -32.4 | -4.83 |